An Integrative Pan-Cancer Analysis Revealing ETS1 as an Oncogenic Immune Protein in Tumor Microenvironment
Abstract BackgroundPrevious research revealed that ETS Proto-Oncogene 1, Transcription Factor (ETS1) might be useful in cancer immunotherapy. However, the processes underlying its therapeutic potential have yet to be thoroughly investigated. The goal of this work was to look into the association between ETS1 expression and immunity and depict its prognostic landscape in pan-cancer. MethodsThe TCGA provides raw data on 33 different types of cancer. GEO gave GSE67501, GSE78220, and IMvigor210. In addition, we looked at ETS1's genetic changes, expression patterns, and survival studies. The researchers investigated the links between ETS1 and the TME and its linkage to immunological processes/elements and the major histocompatibility complex better to understand the importance of ETS1 in cancer immunotherapy. Meanwhile, three distinct immunotherapeutic cohorts were employed to study the relationship between ETS1 and immunotherapeutic response. Finally, PPI analysis and functional gene enrichment were performed using GSEA. ResultsETS1 expression was shown to be higher in tumor tissue on average. Elevated ETS1 expression has been connected to a worse clinical outcome in patients with OS. ETS1 has been linked to immune cell infiltration, immunological modulators, and immunotherapeutic markers. Furthermore, increased ETS1 expression has been connected to immune-related pathways. However, there was no statistically significant link found between ETS1 and immunotherapeutic response. ConclusionsETS1 might be a biomarker for immune infiltration and poor cancer prognosis. It is possible that treatment targets should be researched further.